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Introduction
Patients (pts) with breast cancer (BC) who achieve
complete pathologic response (pCR) to neo-adjuvant
chemotherapy (NAC) have better survival than pts with-
out pCR. It is hypothesized that circulating levels of
MDSC may be a potential predictive biomarker for NAC.
Methods
Pts with operable BC electing to have NAC are eligible. Pts
usually receive an anthracycline (AC) regimen followed by
a taxane (T) (+ trastuzumab for HER-2/neu+ BC).
Circulating levels of MDSC were measured by flow cyto-
metry as a percentage of peripheral blood mononuclear
cells prior to cycle 1, 2 of AC and cycle 1 and 4 of T. If
any other NAC regimen is used, MDSC were measured
prior to 1st, 2nd and last cycle. MDSC were identified as
HLA-DR-, CD11b+, CD33+ cells with granulocytic
(G-MDSC) and monocytic (M-MDSC) subsets expressing
CD15 and CD14, respectively. The 1o objective is to
study the changes in MDSC % in response to NAC. A
sample size of 24 pts (6 with pCR and 18 without pCR)
provides 80% power to detect at least an effect size of
1.5 standard deviation between the responders and non-
responders using a 2 sided, 2 sample t-test with an a
level of 0.05.
Results
To date, 14 of 24 pts have been enrolled (stage I [N=1],
stage II [N=13], triple negative (TN) [N=8], HER-2/neu+
[N=5], hormone receptor (HR)+ [N=1]). Median age is
46 (range 32-69). G-MDSC % and 95% confidence inter-
vals [95% CI] were 1.45 [0.38-2.51], 7.59 [3.40-11.78],
11.76 [3.67-19.85], 3.17 [0 - 7.49] at time points 1-4
respectively. M-MDSC % was smaller but followed a
similar trend. This trend was also seen in pts with TN
and Her-2/neu+ BC but not in 1 pt with HR+ BC who
had persistent increase in MDSC. Of 5 pts who com-
pleted NAC, 4 had pCR. We found that MDSC% initially
increased during NAC but decreased at the end of treat-
ment in pts with pCR (G-MDSC percentages [95% CI]:
0.27 [0-0.76], 9.32 [0.97-16.8], 9.31 [0.45-21.9], 1.22
[0.18-2.31]. Conversely, MDSC % continued to rise in the
pt that did not have pCR (G-MDSC: 0.36, 3.37, 11.3 at
time points 1-3, respectively). M-MDSC % followed the
same trend in patients with or without pCR.
Conclusion
This preliminary data suggests that G-MDSC % at the
end of chemotherapy is low in patients with pCR but
continues to rise in patients who do not respond to che-
motherapy. More data is needed to confirm these results.
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